CARVEDILOL PHOSPHATE

Generic: CARVEDILOL PHOSPHATE

Sun Pharmaceutical IndustriesManufacturer
ORALRoute
CARVEDILOL PHOSPHATEActive Substance
2017-10-25Original Approval

CARVEDILOL PHOSPHATE is FDA application ANDA090132, sponsored by SUN PHARM INDUSTRIES. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class II2025-02-28
Carvedilol Tablets USP 25 mg, 500 -Count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured f

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake

Class II2025-02-28
Carvedilol Tablets USP 12.5 mg, 500-Count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake

Class II2025-08-07
Carvedilol Tablets, USP, 12.5 mg, 500-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bard

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acce

Class II2025-01-22
Carvedilol Tablets, USP, 12.5 mg, Rx only, a)500 Tablets, NDC 68462-164-05; b) 100 Tablets, NDC 68462-164-01, Manufactur

CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA re

Class II2025-01-22
Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured

CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA re

Class II2025-02-28
Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01), b.) 500-count bottle (NDC 68462-162-05),

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake

Class II2025-08-06
Carvedilol Tablets, USP, 25 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above th

Class II2025-02-28
Carvedilol Tablets USP 6.25 mg, a.)100-count bottle (NDC 68462-163-01), b.) 500-count bottle (NDC 68462-163-05) Rx Only,

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake

Class II2025-08-06
Carvedilol Tablets, USP, 12.5 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above th

Class II2025-03-13
Carvedilol Tablets, USP 12.5 mg, 500-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur

CGMP Deviations

Top Reported Reactions

1
FATIGUE
6,552 reports
2
DYSPNOEA
5,931 reports
3
DIARRHOEA
5,459 reports
4
DIZZINESS
4,819 reports
5
NAUSEA
4,663 reports
6
DEATH
4,515 reports
7
DRUG INEFFECTIVE
4,435 reports
8
HYPOTENSION
4,273 reports
9
OFF LABEL USE
3,886 reports
10
ASTHENIA
3,809 reports